Acute or chronic joint inflammation currently or in the past 3 months, not attributable to another condition (Joint Inflammation defined as: At least 1 joint this is swollen, red, or warm to the touch; with or without corresponding tenderness)
Pain visual analog scale (pain VAS) \>=30 at screening
You may not be if
Age \<40 years
Chronic diarrhea
Gout, rheumatoid arthritis, psoriatic arthritis, or cirrhosis
Ongoing use of colchicine and unwilling to undergo a 30-day wash-out period (note: patients using colchicine at screening can enroll if they agree to a 30-day wash-out before randomization)
Pregnant or breast-feeding
Use of methotrexate, hydroxychloroquine, tocilizumab or canakinumab in the past 4 weeks
Use of anakinra, oral glucocorticoid, or intra-articular steroid in the past 1 week
Ongoing use of strong CYP3A4 inhibitors per FDA package insert for colchicine
Ongoing use of P-glycoprotein inhibitors per FDA package insert for colchicine
Known allergy to colchicine
Planned joint surgery in the next 6 months
CPPD clinical presentation isolated to Crowned Dens Syndrome with no additional peripheral joint involvement
Screening labs with any of the following:
1. Hemoglobin \< 9 g/dL
2. WBC \<3 x 10\^9/L
3. Platelets \<110 x10\^9/L
4. Creatinine clearance (CrCl) \<30 mL/min
5. ALT or AST \>3x upper limit of normal (ULN)
Patient is considered by investigator to be an unsuitable candidate for the study for any reason
